Login to Your Account



Genmab 'Celebrating' Return Of Worldwide HuMax-CD4 Rights

By Jennifer Boggs


Monday, July 2, 2007
Genmab A/S said it is moving full steam ahead with its late-stage HuMax-CD4 compound in cutaneous T-cell lymphoma after regaining full rights to the drug from partner Merck Serono SA. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription